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1 Research questions 
The HTA Core Model® for Rapid Relative Effectiveness Assessment of Phar-
maceuticals was used for structuring this report [1]. The Model organises 
HTA information according to pre-defined generic research questions. Based 
on these generic questions, the following research questions were answered 
in this assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is bevacizumab? 
A0022 Who manufactures bevacizumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has bevacizumab received marketing authorisation? 
A0021 What is the reimbursement status of bevacizumab? 
Health problem and current use 
A0002 What is ovarian cancer? 
A0004 What is the natural course of ovarian cancer? 
A0003 What are the known risk factors for ovarian cancer? 
A0005 What are the symptoms and the burden of ovarian cancer? 
A0024 How is ovarian cancer currently diagnosed according to published guidelines and  
in practice? 
A0006 What are the consequences of ovarian cancer for the society? 
A0023 How many people belong to the target population? 
A0025 How is ovarian cancer currently managed according to published guidelines and  
in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of bevacizumab on mortality? 
D0005 How does bevacizumab affect symptoms and findings (severity, frequency) of  
ovarian cancer? 
D0006 How does bevacizumab affect progression of ovarian cancer? 
D0011 What is the effect of bevacizumab on patients’ body functions? 
D0012 What is the effect of bevacizumab on generic health-related quality of life? 
D0013 What is the effect of bevacizumab on disease-specific quality of life? 
Safety 
C0008 How safe is bevacizumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying bevacizumab? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of bevacizumab? 
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2 Drug description 
Generic/Brand name/ATC code:  
Bevacizumab/Avastin®/L01XC07 
 
B0001: What is bevacizumab? 
Bevacizumab (Avastin®) is a recombinant monoclonal antibody that binds to 
the vascular endothelial growth factor (VEGF). By inhibiting VEGF receptor 
binding, bevacizumab prevents the growth and maintenance of tumour blood 
vessels [2]. 
For the front-line treatment of patients with advanced epithelial ovarian, fal-
lopian tube and primary peritoneal cancer, the recommended dose of bevaci-
zumab is 15 mg/kg of body weight given intravenously (IV) once every three 
weeks. It is administered in addition to carboplatin and paclitaxel for up to 
six cycles of treatment followed by continued use as a single agent. If the ini-
tial dose of bevacizumab, which should be delivered over 90 minutes IV, is 
well tolerated, the second infusion can be administered over 60 minutes, fol-
lowed by 30-minute infusions for all subsequent infusions. Treatment should 
be continued until disease progression or for a maximum of 15 months or un-
til unacceptable toxicity, whichever occurs earlier [3].  
The most serious adverse reactions with bevacizumab observed in safety anal-
ysis (including patients with various malignancies) were gastrointestinal per-
forations, haemorrhage and arterial thromboembolism. The most frequent ad-
verse reactions with bevacizumab occurring in patients across clinical trials 
were hypertension, fatigue, asthenia, diarrhoea and abdominal pain. The oc-
currence of hypertension and proteinuria are likely to be dose-dependent [3]. 
 
A0022: Who manufactures bevacizumab? 
Genentech, Inc./Roche 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Bevacizumab (Avastin®), combined with carboplatin and paclitaxel, is indi-
cated for the front-line treatment of adult patients with advanced (FIGO1 
stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peri-
toneal cancer [3]. 
 
 
                                                             
1 FIGO = International Federation of Gynecology and Obstetrics 
bevacizumab  
inhibits growth and 
maintenance of  
tumour blood vessels 
 
 
intravenous 
administration 
most serious/most 
frequent adverse 
reactions 
indicated as first-line 
treatment of advanced 
ovarian cancer 
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4 Current regulatory status 
A0020: For which indications has bevacizumab received  
marketing authorisation? 
Bevacizumab was approved by the EMA in December 2011 for the front-line 
treatment of adults with advanced (FIGO stages IIIB, IIIC and IV) epithelial 
ovarian, fallopian tube or primary peritoneal cancer (in combination with car-
boplatin and paclitaxel) [3]. Bevacizumab is also licensed for the treatment 
of adult patients with first recurrence of platinum-sensitive epithelial ovari-
an, fallopian tube or primary peritoneal cancer who have not received prior 
therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-tar-
geted agents (in combination with carboplatin and gemcitabine) and for the 
treatment of adults with platinum-resistant recurrent epithelial ovarian, fal-
lopian tube or primary peritoneal cancer who received no more than two pri-
or chemotherapy regimens and who have not received prior therapy with be-
vacizumab or other VEGF inhibitors or VEGF receptor-targeted agents (in 
combination with paclitaxel, topotecan or pegylated liposomal doxorubicin). 
Furthermore, the EMA granted marketing authorisation for bevacizumab for 
the following indications [3]: 
 for the treatment of adult patients with metastatic carcinoma of the 
colon or rectum (in combination with fluoropyrimidine-based chemo-
therapy) 
 for the first-line treatment of adults with metastatic breast cancer 
(combined with paclitaxel) 
 for the first-line treatment (in combination with capecitabine) of adult 
patients with metastatic breast cancer in whom treatment with other 
chemotherapy options including taxanes or anthracyclines is not con-
sidered appropriate  
 for the first-line treatment of adult patients with unresectable ad-
vanced, metastatic or recurrent non-small cell lung cancer with other 
than predominantly squamous cell histology (in addition to platinum-
based chemotherapy) 
 for the first-line treatment (combined with interferon alfa-2a) of adults 
with advanced and/or metastatic renal cell cancer 
 for the treatment of adult patients with persistent, recurrent or meta-
static carcinoma of the cervix (in combination with paclitaxel and cis-
platin, or, alternatively, paclitaxel and topotecan). 
In December 2014, the EMA granted orphan designation for bevacizumab 
for the treatment of hereditary haemorrhagic telangiectasia [4]. 
To date, bevacizumab is not approved for the first-line treatment of patients 
with ovarian cancer by the FDA. The FDA granted marketing authorisation 
for bevacizumab for the treatment of [5]: 
 metastatic colorectal cancer, with intravenous 5-fluorouracil-based che-
motherapy for first- or second-line treatment 
 metastatic colorectal cancer, with fluoropyrimidine-, irinotecan- or flu-
oropyrimidine-oxaliplatin-based chemotherapy for second-line treat-
ment in patients who have progressed on a first-line bevacizumab-con-
taining regimen 
approved by the EMA 
for first-line treatment 
of ovarian cancer 
bevacizumab is already 
approved by the EMA 
for several indications 
not approved by the 
FDA for the first-line 
treatment of ovarian 
cancer 
several other indications 
are approved by the 
FDA 
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 non-squamous, non-small cell lung cancer, with carboplatin and pacli-
taxel for first-line treatment of unresectable, locally advanced, recur-
rent or metastatic disease 
 glioblastoma, as a single agent for adults with progressive disease fol-
lowing prior therapy  
 metastatic renal cell carcinoma with interferon alfa  
 cervical cancer, in combination with paclitaxel and cisplatin or pacli-
taxel and topotecan in persistent, recurrent or metastatic disease 
 platinum-resistant recurrent epithelial ovarian, fallopian tube or pri-
mary peritoneal cancer, in combination with paclitaxel, pegylated lip-
osomal doxorubicin or topotecan. 
 
 
 
5 Burden of disease 
A0002: What is ovarian cancer? 
A0004: What is the natural course of ovarian cancer? 
Ovarian cancer develops in the ovaries and is mostly of epithelial origin. Var-
ious subtypes (having prognostic importance) of epithelial ovarian cancer can 
be distinguished: serous, endometrioid, clear cell, mucinous, transitional cell 
(Brenner), mixed epithelial tumours, undifferentiated and unclassified sub-
types [6]. In advanced ovarian cancers, invasive serous carcinomas are the 
most common histological type. 
Ovarian cancer is a potentially metastatic disease that mainly spreads to the 
peritoneum, the omentum and to abdominal and pelvic organs. In advanced 
disease, ovarian cancer can disseminate to the lung and liver or, in rare cas-
es, even to the brain or skin [7]. 
The median age at diagnosis of ovarian cancer is 63 years; the disease is most 
commonly diagnosed among women at the age of 55–64 years. 15% of ovari-
an cancer cases are diagnosed at local stage, 19% at regional stage and 60% at 
distant stage (6% of cases remain unstaged)[8]. 
The survival rate of patients with ovarian cancer depends on the stage of the 
disease. Overall, 45.6% of patients with ovarian cancer survive 5 years. 5-year 
survival rates are 92.1% in patients with localised disease, 73.2% in patients 
with regional disease (cancer has spread to regional lymph nodes), 28.3% in 
patients who have distant metastatic disease and 22.9% in patients with un-
staged disease [8].  
 
A0003: What are the known risk factors for ovarian cancer? 
A strong family history of breast cancer or ovarian cancer is deemed to be the 
most important risk factor for the development of ovarian cancer. Studies in-
dicate that preventive removal of the ovaries and fallopian tubes in women 
who have a history of breast cancer or who have tested positive for inherited 
approx. 90% are of 
epithelial origin 
potentially  
metastatic disease 
median age at diagnosis: 
63 years 
45.6% of patients 
survive 5 years 
family history of 
breast/ovarian cancer  
is the most important 
risk factor 
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mutations in BRCA1 or BRCA22 may decrease their risk [9]. Patients with 
an inherited BRCA1 mutation have a 15–45% lifetime risk of developing ovar-
ian cancer, a BRCA2 mutation increases the lifetime risk of ovarian cancer 
to 10–20% [6]. However, there is evidence showing that 44% of patients with 
high-grade serous ovarian cancer and a germline BRCA mutation had no re-
ported family history of breast or ovarian cancer [6, 10]. 
Further risk factors are pelvic inflammatory disease, Lynch syndrome, the use 
of single-agent oestrogen as menopausal hormone therapy, tobacco smoking 
and heavier body weight. In contrast, pregnancy, the long-term use of oral 
contraceptives and tubal ligation, as well as hysterectomy and salpingectomy 
may reduce the risk for ovarian cancer [9]. 
 
A0005: What are the symptoms of ovarian cancer? 
Since ovarian cancer that is confined to the ovary causes few or no symptoms, 
the disease is difficult to detect in early stages [6]. However, there is evidence 
that some women experience persistent, non-specific symptoms (including 
bloating, pelvic or abdominal pain, difficulty eating, feeling full quickly or 
feeling urinary urgency or frequency) [9]. Symptoms of ovarian cancer of all 
stages are abdominal or pelvic pain, constipation, diarrhoea, urinary frequen-
cy, vaginal bleeding, abdominal distension and fatigue. Symptoms more often 
occur in advanced stages of the disease and include ascites and abdominal 
masses (leading to increased abdominal girth), bloating, nausea, anorexia, 
dyspepsia and early satiety. When the disease spreads to other parts of the 
body, patients may develop respiratory symptoms, or may recognise an ab-
dominal or nodal mass in the inguinal region, axillae or the supraclavicular 
fossa [6]. 
 
A0024: How is ovarian cancer currently diagnosed according  
to published guidelines and in practice? 
Early ovarian cancer rarely causes symptoms when it is confined to the ova-
ries and is therefore difficult to detect [6]. Hence, 70% of epithelial ovarian 
cancers are not discovered until the disease has progressed to advanced stages 
and has spread to other parts of the body [11]. Currently, no sufficient screen-
ing test for the early detection of ovarian cancer in women with an average 
risk for the disease exists [9]. Although the measurement of serum cancer an-
tigen (CA) 125 is used routinely to support diagnosis after conducting a full 
clinical assessment, its fitness for the purpose of detecting ovarian cancer in 
its early stages is questionable [6]. 
The following tests (in addition to a physical examination) may be used for 
diagnosing ovarian cancer [11]:  
 pelvic examination (including uterus, vagina, ovaries and rectum) 
 transvaginal ultrasonography 
 CA 125 assay 
 imaging methods, including X-ray examination, computed tomogra-
phy, positron emission tomography, lower gastrointestinal series and 
magnetic resonance imaging 
 biopsy. 
                                                             
2 BRCA1, BRCA2 = Breast Cancer Genes 1 and 2  
symptoms are rare  
in early stages of disease 
rare early-stage 
symptoms make the 
disease difficult to 
detect 
tests for diagnosis of 
ovarian cancer 
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Ovarian cancer is staged according to the FIGO classification which was updated in 2014 [12]:  
Stage I: 
Tumour confined to ovaries 
IA Tumour limited to 1 ovary, capsule intact, no tumour on surface, negative washing 
IB Tumour involves both ovaries, otherwise like IA 
IC Tumour limited to 1 or both ovaries 
IC2 Capsule rupture before surgery or tumour on ovarian surface 
IC3 Malignant cells in the ascites or peritoneal washings 
Stage II: 
Tumour involves 1 or both ovaries with pelvic extension (below the pelvic brim) or primary peritoneal cancer 
IIA Extension and/or implant on uterus and/or fallopian tubes 
IIB Extension to other pelvic intraperitoneal issues 
Stage III: 
Tumour involves 1 or both ovaries with cytologically or histologically confirmed spread  
to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes 
IIIA Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis 
IIIA1 Positive retroperitoneal lymph nodes only 
IIIA1(i): metastasis ≤ 10 mm 
IIIA1(ii): metastasis > 10 mm 
IIIA2 Microscopic, extrapelvic (above the brim), peritoneal involvement ± positive retroperitoneal 
lymph nodes 
IIIB Macroscopic, extrapelvic, peritoneal metastasis ≤ 2 cm ± positive retroperitoneal lymph nodes; 
includes extension to capsule of liver/spleen 
IIIC Macroscopic, extrapelvic, peritoneal metastasis > 2 cm ± positive retroperitoneal lymph nodes; 
includes extension to capsule of liver/spleen 
Stage IV: 
Distant metastasis excluding peritoneal metastasis 
IVA Pleural effusion with positive cytology 
IVB Hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs (including 
inguinal lymph nodes and lymph nodes outside of the abdominal cavity) 
 
 
A0006: What are the consequences of ovarian cancer for the society? 
A0023: How many people belong to the target population? 
In Austria, the incidence of ovarian cancer is 8.5 per 100,000 women per year; 
653 women were newly diagnosed with ovarian cancer in 2012 [13]. In Eu-
rope, the estimated incidence of ovarian cancer was 13.1 per 100,000 persons 
in 2012 with higher incidence rates in northern European countries (e.g. 18.9 
per 100,000 persons in Latvia or 18.2 per 100,000 in Lithuania) [14]. Assum-
ing that 60% of ovarian cancer cases are diagnosed at a distant stage of the 
disease [8], in Austria, 392 patients would qualify for bevacizumab therapy 
each year. 
 
 
 
incidence in Austria: 
8.5/100,000 women  
per year 
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6 Current treatment 
A0025: How is ovarian cancer currently managed according  
to published guidelines and in practice? 
If ovarian cancer is assumed, appropriate surgical staging and cytoreduction, 
mostly followed by systemic chemotherapy, are conducted as part of the pri-
mary treatment [15]. As most ovarian cancer patients present with advanced 
disease, primary cytoreduction is not only performed to document the stage 
and extent of the disease but also to resect as much visible tumour mass as 
possible [16]. The initial surgery should be conducted as a comprehensive 
staging laparotomy and should include a total abdominal hysterectomy and 
a bilateral salpingo-oophorectomy. In women who wish to maintain fertility, 
a unilateral salpingo-oophorectomy may be appropriate for the treatment of 
tumour stages 1A, 1C and/or low-risk ovarian tumours. Optimal surgical cy-
toreduction is achieved when residual tumour nodules are less than 1 cm in 
maximum diameter or thickness. Minimally invasive procedures and tech-
niques may be used in selected patients for surgical staging and in early-stage 
disease to achieve the surgical goals [15]. 
In primary advanced ovarian cancer, cytoreduction of all visible disease is 
required, including intestinal resection, peritoneal stripping, diaphragmatic 
resection, removal of bulky para-aortic lymph nodes and splenectomy [6]. 
Although the therapeutic benefit of adjuvant chemotherapy is still controver-
sial, it may be considered (followed by interval cytoreduction, which is ad-
ministered after chemotherapy) in patients with bulky stage III to IV disease 
(assessed by a gynaecological oncologist) who are not appropriate for surgery 
[15]. The European Society for Medical Oncolgy (ESMO) strongly recom-
mends offering adjuvant chemotherapy not only to suboptimally staged pa-
tients, but also to patients who are optimally staged at a higher risk of disease 
recurrence [6]. The European Organisation for Research and Treatment of 
Cancer – Gynaecological Oncology Group (EORTC-GOG) defined an optimal 
staging procedure for early ovarian cancer as [17]: 
 inspection and palpation of all peritoneal surfaces 
 biopsies of any suspected lesions 
 peritoneal washings 
 blind biopsies of the right diaphragm and right and left para-colic 
gutter, pelvic side-walls of the ovarian fossa and the bladder peritoneum 
 sampling of iliac and para-aortic lymph nodes. 
For all patients with FIGO stage II–IV disease, chemotherapy is recommend-
ed after surgery. ESMO [6] strongly recommends (IA3) standard chemother-
apy, consisting of combined paclitaxel 175 mg/m2 and carboplatin at an area 
under the curve (AUC) 6–5, both given IV every 3 weeks (usually for 6 cycles). 
For patients developing an allergy or patients who do not tolerate paclitaxel, 
a treatment with the combination of docetaxel and carboplatin or pegylated 
liposomal doxorubicin (PLD) and carboplatin can be considered. Alternative-
                                                             
3 Level/grade of recommendation IA = Evidence from at least one large randomised, 
controlled trial of good methodological quality (low potential for bias) or meta-anal-
yses of well-conducted randomised trials without heterogeneity; strong evidence for 
efficacy with a substantial clinical benefit, strongly recommended 
primary treatment: 
cytoreductive surgery 
and systemic 
chemotherapy 
role of adjuvant 
chemotherapy 
chemotherapy regimens 
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ly, paclitaxel and platinum chemotherapy can be administered in alternative 
schedules, including intraperitoneal administration and dose-dense regimens. 
While these alternative ways of administration may provide an option (e.g. 
in the context of randomised trials), they are not considered standard of care 
[6]. According to the National Comprehensive Cancer Network (NCCN) [15], 
the administration of single-agent platinum agents may provide an appropri-
ate option for patients with poor performance status, comorbidities, stage IV 
disease or elderly patients (< 65 years) who may not tolerate the recommend-
ed regimens. 
ESMO generally recommends (IB4) the addition of bevacizumab to paclitaxel 
and carboplatin in the front-line treatment of patients with advanced ovarian 
cancer showing poor prognostic factors, including stage IV or suboptimal de-
bulking, as defined in the ICON7 trial [6].  
 
 
 
7 Evidence 
A literature search was conducted on 3 November 2015 in four databases 
(The Cochrane Library, CRD Database, Embase, Medline). Search terms were 
“Bevacizumab”, “Avastin”, “Altuzan” “nsc 704865”, “ovarian neoplasms”, 
“ovary cancer”, “newly diagnosed”, “front line”, “first line”. Also, the manu-
facturer was contacted, and it submitted 13 additional references (9 of them 
had already been identified by systematic literature search) and further in-
formation. 
Overall, 386 references were identified. Included in this report were only 
randomised controlled trials: 
 1 phase III trial, assessing the addition of bevacizumab to standard 
chemotherapy in the first-line treatment of ovarian cancer [18, 19]  
 1 phase III trial, evaluating the integration of bevacizumab into  
front-line ovarian cancer therapy [20]. 
 
  
                                                             
4 Level/grade of recommendation IB = Evidence from at least one large randomised, 
controlled trial of good methodological quality or meta-analyses of well-conducted 
randomised trials without heterogeneity; strong or moderate evidence for efficacy but 
with a limited clinical benefit, generally recommended 
bevacizumab:  
generally recommended  
by ESMO 
386 references in total,  
2 phase III trials included  
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7.1 Clinical efficacy and safety – phase III studies 
The ICON7 trial 
The ICON7 trial was conducted to assess the addition of bevacizumab to 
standard chemotherapy (carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 of 
body surface area, given every 3 weeks for 6 cycles) in the first-line treatment 
of women with ovarian cancer; first results were published in 2011 [19]. In 
2015, Oza et al. [18] presented the final analysis of mature overall survival 
(OS) data from ICON7, including detailed data about the effect of bevaci-
zumab according to stage and extent of residual disease after primary debulk-
ing surgery. 
ICON7 was an international, multicentre, open-label, randomised phase III 
trial. A total of 1,528 women with newly diagnosed epithelial ovarian, fallo-
pian tube or primary peritoneal cancer (FIGO stage IIb–IV or high-risk stage 
I–IIa disease) who had undergone debulking cytoreductive surgery (or, in ad-
vanced disease, had a biopsy with no further surgery planned) were enrolled. 
The median age of patients was 57 (range 18–81) years in both groups; the 
majority of patients had Eastern Cooperative Oncology Group (ECOG) per-
formance status 0 or 1, epithelial ovarian (histologically serous) cancer and 
FIGO stage IIIC disease. Detailed patient characteristics including inclusion 
and exclusion criteria can be found in Table 5. 
Patients were randomised in a 1:1 ratio and received either six 3-weekly cy-
cles of IV carboplatin at an area under the curve (AUC) of 5 or 6 mg/ml per 
minute and paclitaxel (175 mg/m2 of body surface area) or the same chemo-
therapy regimen with IV bevacizumab at a dose of 7.5 mg/kg of body weight, 
given concurrently, and continued for 12 further 3-weekly cycles. Bevacizu-
mab was administered about 1 year or until disease progression. Median fol-
low-up was 48.6 months in the standard chemotherapy group and 48.8 months 
in the bevacizumab group (shorter follow-up durations for high-risk patients).  
The primary outcome of ICON7 was progression-free survival (PFS); second-
ary outcomes were OS and safety outcomes including adverse events (AEs), 
laboratory results and worsened ECOG performance status. Exploratory out-
comes were quality of life (= QoL, assessed with the EORTC5 QLQ-C30 and 
QLQ-OV286 questionnaires), health economic and translational research. Re-
sults of these endpoints have already been reported [19]. 
To enable comparison with the GOG-0218 study population (the EMA ap-
proval was based on the results of the GOG-0218 study), risk groups were de-
fined: high risk of progression was defined as stage IV disease, inoperable 
stage III disease or suboptimally debulked (> 1 cm) stage III disease. Patients 
who did not meet the criteria for high-risk disease were defined as non-high-
risk patients. 
 
                                                             
5 EORTC = European Organisation for Research and Treatment of Cancer 
6 QLQ-C30 = quality of life questionnaire – core 30, QLQ-OV28 = quality of life 
questionnaire – ovarian cancer module 
ICON7 trial 
phase III trial with  
1,528 participating 
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patients received 
carboplatin and 
paclitaxel ± 
bevacizumab 
PFS was primary 
outcome 
definition of  
high-risk patients 
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The GOG-0218 trial 
The GOG-0218 trial [20] was an international, double-blind, placebo-con-
trolled phase III trial. 1,873 women were enrolled and randomly assigned to 
3 study regimens, each comprising 22 3-week cycles. Initially, all patients re-
ceived standard chemotherapy for the first 6 cycles, consisting of carboplatin 
(AUC 6) and paclitaxel at a dose of 175 mg/m2 of body surface. Patients of 
the control group received chemotherapy in addition to placebo from cycles 
2 through 22. Patients of the bevacizumab-initiation group received chemo-
therapy, followed by bevacizumab (15 mg/kg) added in cycles 2 through 6 and 
placebo added in cycles 7 through 22. Patients who were assigned to the be-
vacizumab-throughout group received chemotherapy with bevacizumab add-
ed in cycles 2 through 22. Treatment was discontinued in case of disease pro-
gression, the occurrence of unacceptable toxic effects, completion of all 22 cy-
cles or withdrawal. Median follow-up at the time of the primary analysis was 
17.4 months. 
Enrolled patients had previously untreated, incompletely resectable stage III 
or any stage IV epithelial ovarian, primary peritoneal, or fallopian tube can-
cer. The median age of patients was 60 years, with a wide range from 22 to 
89 years. The majority of patients had a Gynecologic Oncology Group (GOG) 
performance status of 0 or 1 and presented with serous adenocarcinomas. De-
tailed patient characteristics including inclusion and exclusion criteria can 
be found in Table 6. 
Initially, the primary endpoint of the GOG-0218 trial was OS. Since numer-
ous investigators and patients contested the continued blinding of the treat-
ment assignments after disease progression, the primary endpoint was changed 
to PFS. Further endpoints were safety and QoL, which were assessed by the 
use of the Trial Outcome Index of the Functional Assessment of Cancer Ther-
apy – Ovary (FACT-O TOI). 
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of bevacizumab on mortality? 
ICON7 
There was no significant difference in OS between the randomised groups, 
neither clinically nor statistically. Due to the evidence of non-proportionality, 
the restricted mean survival was estimated in each group. Restricted mean 
survival was 44.6 months (95% CI, 43.2 to 45.9) for patients receiving stand-
ard chemotherapy, compared to 45.5 months (44.2 to 46.7) in patients receiv-
ing additional bevacizumab. Restricted mean OS time in high-risk patients 
was 39.3 months (95% CI, 37.0 to 41.7) for patients of the bevacizumab group 
and 34.5 months (95% CI, 32.0 to 37.0) for patients of the chemotherapy group 
(log-rank p = 0.03). In non-high-risk patients, the restricted mean survival 
time did not differ significantly between the standard chemotherapy group 
(49.7 months, 95% CI, 48.3 to 51.1) and the bevacizumab group (48.4 months, 
47.0 to 49.9, p = 0.20). During the study, 46% of standard chemotherapy-
group patients and 47% of bevacizumab-group patients died. 
Analyses according to survival by stage, residual disease burden and risk of 
recurrence showed an increased benefit for the addition of bevacizumab to 
standard chemotherapy with worsening prognostic factors (e.g. in high-risk 
patients and patients with disease stage III, IV or inoperable disease).  
GOG-0218 trial 
 
phase III trial of 
standard chemotherapy 
± bevacizumab in  
1,873 women 
newly diagnosed 
ovarian cancer 
primary endpoint was 
changed during the trial 
ICON7:  
no significant OS benefit 
of bevacizumab in  
either group 
 
 
benefit of +4.8 months 
in restricted mean OS  
in high-risk patients  
benefit in patients  
with worsening 
prognostic factors 
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There was no benefit reported from adding bevacizumab in other predefined 
poor-prognosis tumour types, including clear-cell tumours, low-stage high-
grade tumour and low-grade serous tumours. 
GOG-0218 
Median OS was 38.7 months in patients of the bevacizumab-initiation group, 
39.7 months in patients of the bevacizumab-throughout group and 39.3 months 
in patients of the control group. Compared with the control group, the HR 
of death was 1.04 (95% CI, 0.83 to 1.29, p = 0.76) in the bevacizumab-initia-
tion group and 0.92 (95% CI, 0.73 to 1.15, p = 0.45) in the bevacizumab-
throughout group. There were no significant differences in OS among the 
three treatment groups.  
At the time of primary analysis, 76.3% of study patients were alive.  
 
D0006: How does bevacizumab affect progression of ovarian cancer? 
ICON7 
Perren et al. reported PFS results of ICON7 in 2011 [19]: at the time of the 
primary analysis, restricted mean PFS at 36 months was 20.0 months in pa-
tients receiving standard chemotherapy and 21.8 months in patients receiv-
ing standard chemotherapy with bevacizumab; HR for progression or death 
with bevacizumab added was 0.81 (95% CI, 0.70 to 0.94, p = 0.004 by log-
rank test). At the time of the updated analysis, restricted mean PFS was 20.6 
months (standard chemotherapy group) and 22.5 months (bevacizumab group) 
at 36 months and 22.4 months (standard chemotherapy group) compared to 
24.1 months (bevacizumab group) at 42 months (HR for progression or death 
in the bevacizumab group was 0.87, 95% CI, 0.77 to 0.99, p = 0.04), which 
corresponds to a long-term improvement in PFS with bevacizumab compared 
to standard chemotherapy.  
In 2015, Oza et al. presented an updated analysis of PFS [18], showing that 
the overall difference in PFS was no longer statistically significant between 
the randomised groups. In high-risk patients, a significant benefit of p = 0.001 
remained (with strong evidence of non-proportional hazards of p < 0.0001 
and longer mean restricted PFS in the bevacizumab group than in the chem-
otherapy group). 
GOG-0218 
The median PFS was 11.2 months in patients of the bevacizumab-initiation 
group, 14.1 months in the bevacizumab-throughout group and 10.3 months 
in patients of the control group. HR (compared to the control group) for 
progression or death was lower (0.908, 95% CI, 0.795 to 1.040, p = 0.16) in 
the bevacizumab-initiation group and significantly lower (0.717, 95% CI, 
0.625 to 0.824, p < 0.001) in the bevacizumab-throughout group. Compared 
with control treatment, the estimated treatment effect of bevacizumab-through-
out on PFS was consistent across various prognostic factors including cancer 
stage, histologic tumour type and tumour grade, GOG performance status 
and age of patients.  
As required by regulatory agencies, an analysis of PFS with censored data of 
patients with increased CA-125 levels was performed: median PFS was 18.0 
months in the bevacizumab-throughout group versus 12.0 months in the con-
trol group (HR = 0.645, 95% CI, 0.551 to 0.756, p < 0.001).  
no benefit in poor-
prognosis tumour types 
GOG-0218:  
no significant 
differences in OS among 
treatment groups 
ICON7:  
bevacizumab improved 
restricted mean PFS  
(+ 1.8 months) 
updated analysis:  
overall difference in PFS 
no longer statistically 
significant  
GOG-0218:  
bevacizumab prolongs 
PFS when added to 
standard therapy  
(+ 0.9–3.8 months) 
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D0005: How does bevacizumab affect symptoms and findings  
(severity, frequency) of ovarian cancer? 
ICON7 
Perren et al. assessed the best overall response: the rate of complete or par-
tial remission was 48% in the standard chemotherapy group compared to 
67% in the bevacizumab group (difference of 19 percentage points (95% CI, 
11 to 28, p < 0.001). 
GOG-0218 
There was no response rate data available from the GOG-0218 trial. 
 
D0011: What is the effect of bevacizumab on patients’ body functions? 
No evidence was found to answer this research question. 
 
D0012: What is the effect of bevacizumab on generic health-related  
quality of life? 
D0013: What is the effect of bevacizumab on disease-specific quality of life? 
ICON7 
In 2013, Stark et al. [21] presented QoL outcomes of the ICON7 trial, con-
cluding that continuing bevacizumab in patients with ovarian cancer is ap-
parently associated with a small but clinically significant decrement in QoL 
as compared to standard treatment.  
Updated analysis of Oza et al. [18], including data up to week 76, showed 
that there was no difference in global QoL between patients receiving stand-
ard chemotherapy and patients receiving bevacizumab at week 76 (p = 0.43). 
Further exploratory analyses were conducted, showing a clinically small dif-
ference in patients of the non-high-risk bevacizumab group relative to pa-
tients not receiving bevacizumab (–5.1 points, 95% CI –9.4 to –0.7, p = 0.02), 
whereas a small and not significant benefit of +4.3 points (95% CI, –4.9 to 
13.4, p = 0.36) relative to patients not receiving bevacizumab was recorded 
in high-risk patients. 
GOG-0218 
Results of the FACT-O TOI showed no significant differences across the three 
treatment groups. Generally, the mean FACT-O TOI scores increased over 
the duration of the study. During the chemotherapy phase, mean scores were 
slightly lower in both bevacizumab groups as compared to the control group. 
After completion of the chemotherapy, there were no significant differences 
in the FACT-O TOI mean scores between the bevacizumab-throughout group 
and the control group [20, 22]. 
 
higher response rate in 
the bevacizumab group 
ICON7:  
no difference in global 
QoL between the groups 
GOG-0218:  
no significant differences 
in QoL across the  
3 treatment groups 
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Table 1: Efficacy results of the ICON7 trial  
Descriptive 
statistics 
and 
estimate 
variability 
Treatment group 
All patients High-risk patients 
Bevacizumab Standard therapy Bevacizumab Standard therapy 
Number of subjects n = 764 n = 764 n = 248 n = 254 
Median OS (95% CI), 
months 
58.0  
(52.4–66.9) 
58.6  
(53.5–67.5) 
39.7  
(36.0–44.2) 
30.2  
(27.0–34.3) 
Median PFS (95% CI), 
months 
19.9  
(19.1–22.0) 
17.5  
(15.7–18.7) 
16.0  
(14.2–17.8) 
10.5  
(9.3–12.0) 
QoL score, mean (sd) 
Baseline 
Week 76 
Sensitivity  
analysis 
 
54.7 (19.1) 
72.6 (18.9) 
NR 
 
57.0 (20.0) 
75.9 (19.3) 
NR 
 
51.5 (19.8) 
76.7 (18.0) 
63.5 (15.3) 
 
54.1 (20.1) 
72.4 (19.4) 
61.4 (14.2) 
 Bevacizumab  
n = 257 
Standard therapy  
n = 263 
Response (95% CI), %  
Responders (CR/PR) 
Non-responders (SD/PR) 
CR 
PR 
SD 
PD 
 
67 
33 
15.2 
52.0 
29.2 
3.6 
 
48 
52 
4.8 
42.9 
45.7 
6.5 
Effect 
estimate 
per 
comparison 
Comparison groups 
All patients High-risk patients 
Bevacizumab 
vs. Standard 
chemotherapy 
Bevacizumab  
vs. Standard 
chemotherapy 
OS HR 0.99 0.78 
95% CI 0.85–1.14 0.63–0.97 
Unstratified log-rank test p value 7 0.85 0.03 
Non-proportionality p value 8 0.02 0.01 
PFS HR 0.93 0.73 
95% CI 0.83–1.05 0.61–0.88 
Log-rank test p value 0.25 0.001 
Non-proportionality p value < 0.0001 < 0.0001 
QoL 
Week 76/Sensitivity analysis 
HR NR NR 
P value 0.43/NR 0.36/0.36 
CR + PR (bevacizumab:  
n = 257,  
standard therapy: n = 263 
Percentage points, difference 19 
95% CI 11–28 
P value < 0.001 
Abbreviations: CI = confidence interval, CR = complete remission, HR = hazard ratio, n = number, OS = overall survival, 
PD = progressive disease, PFS = progression-free survival, PR = partial remission, QoL = quality of life, sd = standard 
deviation, SD = stable disease 
Sources: [18, 19] 
 
  
                                                             
7 Primary analysis used an unstratified log-rank test to compare OS between the randomised groups 
8 Grambsch-Therneau test 
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Table 2: Efficacy results of the GOG-218 trial  
Descriptive statistics 
and estimate variability Treatment group 
Bevacizumab 
initiation 
Bevacizumab 
throughout 
Control 
Number of subjects n = 625 n = 623 n = 625 
Median PFS (95% CI), months 11.2 14.1 10.3 
Median OS (95% CI), months 38.7 39.7 39.3 
Quality of life NR NR NR 
Effect estimate per 
comparison 
Comparison groups Bevacizumab  
Initiation vs. 
Control 
Bevacizumab 
Initiation vs. 
Control 
Bevacizumab 
throughout vs. 
Control 
PFS HR 0.908 0.717 
95% CI 0.795–1.040 0.625–0.824 
P value 0.16 < 0.001 
OS HR 1.036 0.915 
95% CI 0.827–1.297 0.727–1.152 
P value 0.76 0.45 
QoL, mean FACT-O TOI scores 
(during chemotherapy phase) 
Reduction of points 2.7 3.0 
98.3% CI 0.88–4.57 1.13–4.78 
P value < 0.001 0.001 
Notes  19% of patients completed the planned treatment 
 15% of patients were still receiving treatment at the time of database lock 
 66% of the study population discontinued the study treatment prematurely,  
mostly due to disease progression 
Abbreviations: CI = confidence interval, FACT-O TOI = Trial Outcome Index of the Functional Assessment of Cancer  
Therapy – Ovarian, HR = hazard ratio, n = number, NR = not reported, OS = overall survival, PFS = progression-free 
survival, QoL = quality of life 
Source: [20] 
7.1.2 Safety 
C0008: How safe is bevacizumab in relation to the comparator(s)? 
C0002: Are the harms related to dosage or frequency of applying bevacizumab? 
C0005: What are the susceptible patient groups that are more likely  
to be harmed through the use of bevacizumab? 
ICON7 
AEs of grade 3 or higher were reported in 66% of patients in the bevacizum-
ab group compared to 56% of patients in the standard chemotherapy group. 
Bleeding (mainly grade 1 mucocutaneous bleeding), hypertension of grade 2 
or higher, thromboembolic events of grade 3 or higher and gastrointestinal 
perforations occurred more frequently in the bevacizumab group than in the 
standard chemotherapy group. In total, 5 patients died due to treatment or due 
to treatment and disease: one death was reported from the standard chemo-
therapy group (caused by central nervous system ischaemia) and four patients 
died in the bevacizumab group (caused by gastrointestinal perforation, intra-
cerebral haemorrhage, recurrent bowel perforation and ovarian cancer, and 
neutropenic sepsis and ovarian cancer). According to Oza et al. [18], the fol-
lowing AEs occurred during the extended follow-up: one treatment-related 
grade 3 event (gastrointestinal fistula/bevacizumab group), 3 grade 2 treat-
ment-related AEs in the bevacizumab group (cardiac failure, sarcoidosis, foot 
fracture) and 1 grade 1 treatment-related AE (vaginal haemorrhage) in a pa-
tient treated with standard chemotherapy. 
bleeding, hypertension, 
thromboembolic and 
gastrointestinal events 
were more common 
with bevacizumab 
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GOG-0218 
Hypertension of grade 2 or higher was significantly (p < 0.001) more com-
mon in the bevacizumab-initiation group (16.5%) and in the bevacizumab-
throughout group (22.9%) than in the control group (7.2%). Hence, 2.4% of 
the patients of the bevacizumab-throughout group discontinued study treat-
ment. 
Concerning other selected AEs, including gastrointestinal events (perfora-
tion, fistula, necrosis or anastomotic leak), proteinuria, of grade 3 or higher, 
neutropenia of grade 4 or higher, neutropenia, venous or arterial thrombosis 
and wound disruption, no significant differences among the 3 treatment groups 
were reported. Other AEs, including clinically relevant bleeding or central 
nervous system complications were rare. 
Fatal AEs occurred in 1.6% of patients of the bevacizumab-initiation group, 
in 2.3% of patients of the bevacizumab-throughout group compared to 1.0% 
of patients of the control group. 
Most AEs occurred during the chemotherapy phase, with the exception of 
hypertension, proteinuria and pain, which occurred more commonly during 
the extended-therapy phase in patients of the bevacizumab-throughout group. 
Due to AEs, treatment was discontinued in 15% (bevacizumab-initiation 
group), 17% (bevacizumab-throughout group) and 12% (control group) of 
patients respectively. 76% of AEs leading to discontinuation of study treat-
ment occurred during the chemotherapy phase. 
Table 3: Most frequent adverse events of the ICON7 trial  
Adverse event  
(according to CTCAE version 3.0) 
Bevacizumab  
(n = 745) 
Standard chemotherapy  
(n = 753) 
 None 
n (%) 
Grade 1 or 2 
n (%) 
Grade 3 or 4 None 
n (%) 
Grade 1 or 2 
n (%) 
Grade ≥ 3 
Any event 0 254 (34) 483 (65) 3 (< 1) 331 (44) 410 (54) 
Any event (grade 5) 8 (1) 9 (1) 
Any bleeding 450 (60) 286 (38) 9 (1) 666 (88) 85 (11) 2 (< 1) 
Bleeding other than 
mucocutaneous, tumour-
associated, or within CNS 
688 (92) 55 (7) 2 (< 1) 712 (95) 39 (5) 2 (< 1) 
Mucocutaneous bleeding 469 (63) 271 (36) 5 (1) 698 (93) 55 (7) 0 
Tumour-associated bleeding 0 0 0 0 0 0 
Bleeding within CNS 743 (99) 0 2 (< 1) 753 (100) 0 0 
Abscess and fistula 732 (98) 7 (1) 6 (1) 743 (99) 3 (< 1) 7 (1) 
Gastrointestinal perforation 735 (99) 0 10 (1) 750 (99) 0 3 (< 1) 
Hypertension 552 (74) 57 (8)/90 (12) 46 (6) 706 (94) 45 (6) 2 (< 1) 
Proteinuria 712 (96) 29 (4) 4 (1) 734 (97) 18 (2) 1 (< 1) 
Any thromboembolic event 665 (89) 29 (4) 51 (7) 708 (94) 22 (3) 23 (3) 
Venous thromboembolic event 695 (93) 18 (2) 32 (4) 722 (96) 18 (2) 13 (2) 
Arterial thromboembolic event 718 (96) 7 (1) 20 (3) 742 (99) 1 (< 1) 10 (1) 
Local thrombosis 740 (99) 5 (1) 0 750 (99) 3 (< 1) 0 
Neutropenia 534 (72) 88 (12) 123 (17) 534 (71) 105 (14) 114 (5) 
Febrile neutropenia 724 (97) 2 (< 1) 19 (3) 738 (98) 1 (< 1) 14 (2) 
Thrombocytopenia 652 (88) 67 (9) 26 (3) 684 (91) 54 (7) 15 (2) 
hypertension was 
significantly more 
common with 
bevacizumab 
fatal AEs more frequent 
with bevacizumab 
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Adverse event  
(according to CTCAE version 3.0) 
Bevacizumab  
(n = 745) 
Standard chemotherapy  
(n = 753) 
 None 
n (%) 
Grade 1 or 2 
n (%) 
Grade 3 or 4 None 
n (%) 
Grade 1 or 2 
n (%) 
Grade ≥ 3 
Reversible posterior leuko-
encephalopathy syndrome 
0 0 0 0 0 0 
Congestive heart failure 742 (99) 1 (< 1) 2 (< 1) 750 (99) 0 3 (< 1) 
Complication of wound healing 708 (95) 27 (4) 10 (1) 737 (98) 13 (2) 3 (< 1) 
Hyperbilirubinaemia 742 (99) 2 (< 1) 0 753 (100) 0 0 
Abbreviations: CNS = central nervous system, n = number 
Sources: [18, 23, 24] 
Table 4: Selected adverse events of the GOG-218 trial9  
Adverse event  
(according to NCI-CTCAE version 3.0) 
Bevacizumab initiation 
(n = 607) 
Bevacizumab throughout 
(n = 608) 
Control 
(n = 601) 
 n (%) n (%) n (%) 
Gastrointestinal events (grade ≥ 2) 17 (2.8) 16 (2.6) 7 (1.2) 
Hypertension (grade ≥ 2) 100 (16.5) 139 (22.9) 43 (7.2) 
Proteinuria (grade ≥ 3) 4 (0.7) 10 (1.6) 4 (0.7) 
Pain (grade ≥ 2) 252 (41.5) 286 (47.0) 250 (41.6) 
Neutropenia (grade ≥ 4) 384 (63.3) 385 (63.3) 347 (57.7) 
Febrile neutropenia 30 (4.9) 26 (4.3) 21 (3.5) 
Venous thromboembolism 32 (5.3) 41 (6.7) 35 (5.8) 
Arterial thromboembolism 4 (0.7) 4 (0.7) 5 (0.8) 
Wound disruption 22 (3.6) 18 (3.0) 17 (2.8) 
CNS bleeding 0 2 (0.3) 0 
Non-CNS bleeding (grade ≥ 3) 8 (1.3) 13 (2.1) 5 (0.8) 
Reversible posterior 
leukoencephalopathy syndrome 
1 (0.2) 1 (0.2) 0 
Abbreviations: CNS = central nervous system, n = number, NCI-CTCAE = National Cancer Institute – Common Terminology 
Criteria for Adverse Events 
Source: [20] 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of bevacizumab? 
In Austria, bevacizumab (Avastin®) is available in vials of 4 ml (25 mg/ml) at 
€ 414.05 and vials of 16 ml (25 mg/ml) at € 1,421.90 [25].  
In patients with advanced epithelial ovarian, fallopian tube and primary per-
itoneal cancer, the recommended and EMA-approved dose is 15 mg/kg of body 
weight given IV once every 3 weeks [3]. According to this treatment regimen 
(assuming an average body weight of 70 kg), costs for one dose of bevacizumab 
are € 4,086 (2 x 16 ml vial + 3 x 4 ml vial); for one year of bevacizumab treat-
ment, costs of € 70,824 would incur. 
                                                             
9 Selected AEs with onset between cycle 2 and 30 days after the date of the last treatment 
approved at a dosage  
of 15 mg/kg every  
3 weeks 
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In the ICON7 trial, a different dosing regimen was used: bevacizumab was 
administered at a dose of 7.5 mg/kg of body weight every 3 weeks. Assuming 
an average body weight of 70 kg, one dose of bevacizumab costs € 2,250 (1 x 
16 ml vial + 2 x 4 ml vials). Patients received 6 cycles of standard chemo-
therapy with or without bevacizumab, which was given concurrently and con-
tinued for 12 further 3-weekly cycles, with an overall duration of bevacizumab 
exposure of about one year (or until disease progression). For one year of 
bevacizumab, costs of € 39,000 would incur.  
At any rate, the costs for bevacizumab incur in addition to the costs of stand-
ard chemotherapy. 
 
 
 
9 Ongoing research 
In December 2015, a search in www.clinicaltrials.gov and   
www.clinicaltrialsregister.eu was conducted. The following phase IV and 
phase III trials, evaluating the use of bevacizumab for the first-line treatment 
of ovarian cancer, were identified: 
 NCT01706120: A multicentre phase IV study in patients with stage 
III–IV epithelial ovarian cancer treated with carboplatin + paclitaxel 
with bevacizumab, assessing clinical and biological prognostic factors 
(MITO-16/MANGO2). Estimated study completion date is July 2016. 
 NCT01081262: A multicentre, open-label phase III trial of carboplatin 
and paclitaxel with or without bevacizumab, compared with oxali-
platin and capecitabine with or without bevacizumab as first-line ther-
apy in patients with mucinous epithelial ovarian or fallopian tube can-
cer (MEOC). Estimated primary completion date is July 2020. 
 NCT01462890: A prospective, randomised phase III trial to evaluate 
the optimal treatment duration of first-line bevacizumab in combina-
tion with carboplatin and paclitaxel in patients with primary epithe-
lial ovarian, fallopian tube or peritoneal cancer (BOOST). Estimated 
study completion date is November 2021. 
 NCT01167712: A phase III trial of every-3-weeks paclitaxel vs. dose-
dense weekly paclitaxel in combination with carboplatin with/without 
concurrent and consolidation bevacizumab in the treatment of prima-
ry stage II, III or IV epithelial ovarian, peritoneal or fallopian tube 
cancer and ACRIN 6695: perfusion CT imaging to evaluate treatment 
response in patients participating in GOG-0262. Estimated study com-
pletion date is December 2015. 
 NCT00951496: A phase III trial of bevacizumab with IV versus IP 
chemotherapy in ovarian, fallopian tube and primary peritoneal car-
cinoma. Estimated primary completion date is March 2016. 
one dose of 
bevacizumab costs  
€ 2,250 
 
dose-dependent: 
€ 39,000 to € 70,824  
for 12 months 
1 phase IV, 4 phase III 
and various phase II and 
observational studies 
are ongoing 
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Furthermore, bevacizumab for the first-line therapy in patients with ovarian 
cancer is evaluated in the following phase II studies, in different settings and 
combinations: 
 NCT00511992: A phase II study of paclitaxel, cisplatin IP and bevaci-
zumab IV followed by bevacizumab consolidation for advanced ovari-
an and peritoneal carcinoma or fallopian tube cancer. 
 NCT01097746: A phase II trial of bevacizumab with carboplatin and 
weekly paclitaxel as first-line treatment in epithelial ovarian, primary 
peritoneal and fallopian tube carcinoma. 
 NCT01010126: A phase II trial of temsirolimus and bevacizumab in 
patients with endometrial, ovarian, hepatocellular carcinoma, carcin-
oid or islet cell cancer. 
 NCT01847677: A randomised, multicentre, open-label phase II trial to 
determine the efficacy and toxicity of preoperative chemotherapy with/ 
without bevacizumab in patients with advanced ovarian cancer (NOVA). 
Additionally, various observational studies were identified, assessing the use 
of bevacizumab for the front-line treatment of ovarian cancer (e.g. ENCOUR-
AGE trial, BOVARI trial and OSCAR trial). 
 
 
 
10 Discussion 
Since 2011, bevacizumab (Avastin®), in combination with carboplatin and pac-
litaxel, has been approved by the EMA for the front-line treatment of women 
with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian 
tube or primary peritoneal cancer [26]; the FDA has not granted marketing 
authorisation for this indication yet.  
The EMA approval was based on the efficacy and safety results of two phase 
III trials, evaluating the addition of bevacizumab to the front-line treatment 
with carboplatin and paclitaxel: the ICON7 trial and the GOG-0218 trial [3].  
The two trials differed significantly in their setting and study design [27]: 
ICON7 was an open-label, two-arm study; patients received bevacizumab for 
12 months at a dosage of 2.5 mg/kg per week. In contrast, the GOG-0218 trial 
was double-blind, placebo-controlled and conducted as a 3-arm study; bevaci-
zumab was administered for 15 months at a dose of 5 mg/kg per week. Fur-
thermore, the patient populations differed: in the ICON7 trial, patients with 
stage I or IIA (up to 10 %) and with stages IIB to IV (all) participated; in the 
GOG-0218 trial, patients had stage III (suboptimal, optimal or visual/palpab-
le) and stage IV disease. In contrast to the GOG-0218 trial, there was no in-
dependent review committee in the ICON7 trial [27]. The primary endpoint 
of the ICON7 trial was PFS, OS was defined as a secondary outcome [18]. In 
the GOG-0218 study, OS was initially defined as the primary endpoint which 
was then changed to PFS [20]. Since numerous investigators and patients con-
tested the maintenance of blinding the treatment assignments after disease 
progression, the primary endpoint was changed, causing a major limitation of 
the GOG-0218 trial [20]. Safety and quality of life were endpoints of both tri-
als. According to the National Institute for Health and Care Excellence (NICE) 
indication approved  
by the EMA, but not  
by the FDA 
approval based on 
ICON7 and GOG-0218 
differences between 
phase III trials 
 
 
 
 
 
 
 
 
major limitation  
of GOG-0218:  
change of endpoint 
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[28], the two trials are difficult to compare as they differ regarding inclusion 
criteria, administered bevacizumab dose, duration of treatment, definitions of 
progression and optimal debulking as well as in baseline factors. 
Although both trials [18–20] initially showed an improvement of PFS when 
bevacizumab was added to standard chemotherapy, the overall benefit for the 
patients was modest. In the ICON7 trial, an updated analysis (results pub-
lished in 2015 [18]) even showed no difference in PFS between the treatment 
groups. Regarding OS, there was no significant difference between the treat-
ment groups in both trials: in the ICON7 trial, a gain of 0.9 months in re-
stricted mean survival has been shown; patients of the GOG-0218 trial did 
not achieve any gain in OS by receiving study treatment. However, the bene-
fits in OS and PFS were greater among patients who had a high risk for pro-
gression than in lower-risk patients. The benefit in restricted mean survival 
for high-risk patients of the ICON7 trial was 4.8 months when bevacizumab 
was added to standard chemotherapy. There were no significant differences 
in the quality of life of patients of both trials.  
Generally, AEs were more frequent in patients who received additional bevaci-
zumab compared to standard chemotherapy. In the ICON7 trial [18], AEs of 
grade 3 or higher occurred more frequently in patients of the bevacizumab 
group compared to chemotherapy-group patients (66% vs. 56% respectively). 
Bleeding, hypertension (≥ grade 2), thromboembolic events and gastrointes-
tinal perforation were more common with bevacizumab. 5 Patients died due 
to treatment or to treatment and disease. In the GOG-0218 trial [20], hyper-
tension (≥ grade 2) occurred significantly more frequent in patients receiving 
bevacizumab; fatal AEs were most frequent in the bevacizumab-throughout 
group, compared to the bevacizumab-initiation group and the control group 
(2.3% vs. 1.6% and 1.0% respectively). A meta-analysis [29] including 4 ran-
domised controlled trials (ICON7, GOG-0218 and two trials evaluating bevaci-
zumab for the treatment of platinum-resistant recurrent ovarian cancer and 
platinum-sensitive recurrent ovarian cancer respectively) showed a signifi-
cantly increased risk of gastrointestinal events, hypertension, proteinuria and 
arterial thromboembolism with bevacizumab, whereas there was no evidence 
of a significant increased risk of venous thromboembolism. Results from a 
further meta-analysis [30] including the same 4 randomised controlled trials 
showed that the combination of bevacizumab with chemotherapy increases 
non-CNS bleeding, hypertension grade ≥2, arterial thromboembolism, gas-
trointestinal perforation and proteinuria grade ≥3. 
Important issues to discuss are the role and the applicability of the results of 
the ICON7 trial, considering that an unlicensed dose of bevacizumab has been 
used. According to ESMO, bevacizumab is not consistently used in Europe, 
as some clinicians restrict the use to „higher-risk” patients (as defined in the 
ICON7 trial), some use bevacizumab in its licensed dose and indication and 
others administer the drug to patients with recurrent ovarian cancer [6]. How-
ever, the EMA recommended the use of 15 mg/kg of bevacizumab every 3 
weeks, which differs from the dose used in the ICON7 trial (7.5 mg/kg) and 
makes the results difficult to compare to phase III data from the GOG-0218 
trial. More importantly, the use of a lower dose of bevacizumab than the ap-
proved dose would halve the treatment costs. More data concerning the op-
timal dose and duration of bevacizumab in the front-line setting is required. 
The results of the BOOST trial (NCT01462890), evaluating the optimal treat-
ment duration of first-line bevacizumab, may help to resolve this issue. Accord-
ing to information from the manufacturer, results of the primary analysis of 
the BOOST trial are expected for the second half of 2016. First results from 
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the ROSiA trial (NCT01239732), a study evaluating the addition of bevacizu-
mab to standard chemotherapy for the first-line treatment in patients with ovar-
ian cancer with a median number of 23 (range 1–61, median exposure dura-
tion of 15.5 months) administered cycles, indicate that the longer duration of 
bevacizumab exposure may improve PFS but may also increase toxicity [31]. 
Another unresolved issue is the selection of the most appropriate patient pop-
ulation for the addition of bevacizumab to standard chemotherapy. With re-
spect to personalised medicine for affected patients, more research is needed 
to identify molecular markers [6]. The use of biomarkers that can predict the 
therapeutic effect of bevacizumab therapy would enable a more effective ad-
ministration [32]. Since results of both phase III trials showed an improved 
efficacy in patients of the high-risk subgroups; further investigation is need-
ed in this special group of patients.  
ESMO generally recommends the use of bevacizumab for patients with ad-
vanced ovarian cancer with poor prognostic features (e.g. stage IV or subop-
timal debulking) [6]. Likewise, NCCN recommends the addition of bevaci-
zumab to the upfront chemotherapy of ovarian cancer; however, the recom-
mendation is classified as “category 3”, based on any level of evidence and 
with major objections by NCCN on the grounds that the intervention is ap-
propriate. The disagreement among panel members is caused by a lack of sig-
nificant benefit in OS and QoL in phase III data from randomised trials. If 
bevacizumab is administered with first-line chemotherapy followed by bevaci-
zumab maintenance, the panel recommends the (category 3) administration 
of regimens used in the GOG-0218 or ICON7 trials [15]. NICE [28] does not 
recommend bevacizumab given with paclitaxel and carboplatin for the first-
line treatment of advanced ovarian cancer (only the results of GOG-0218 were 
accepted as key evidence and were supported by the ICON7 results).  
However, NICE noted that, for patients with advanced ovarian cancer whose 
treatment options are limited, bevacizumab provides an additional option. 
Moreover it was concluded that compared with chemotherapy alone, the com-
bination regimen did not lead to unacceptable toxicity, and occurring AEs 
were manageable. Furthermore, NICE stressed not to underestimate the im-
pact of any PFS prolongation for the patients and their families [28]. Also, 
the impact of patient crossover from the control arm on the overall survival 
results was discussed. However, the addition of bevacizumab to standard 
chemotherapy for the first-line treatment of ovarian cancer was not recom-
mended due to its lack of cost-effectiveness [28].  
Generally, adding bevacizumab to standard chemotherapy in the front-line 
treatment of advanced ovarian cancer in the overall cancer population has not 
been considered cost-effective by several authors [33–35]. However, the com-
bination regimen might become effective with biosimilar bevacizumab (which 
is currently in development in 7 companies) administered in patients with 
stage IV disease, ECOG performance status 1 and in patients at high risk of 
disease progression [34]. In the course of the expiration of the product pa-
tent on bevacizumab in July 2019 (in the US) and 2018 (in the EU) [34], the 
administration of biosimilar bevacizumab may become relevant. 
However, no significant improvement in OS has been shown for the addition 
of bevacizumab to standard therapy among the entire (high-risk and non-
high-risk patients) patient population of the ICON7 and GOG-0218 trials. 
This fact is supported by Mahner et al., who showed that no reliable effect of 
any anti-angiogenic agent on OS could be observed to date [36]. Additionally, 
no significant improvement in the quality of life of patients has been recorded. 
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In conclusion, the addition of bevacizumab to standard chemotherapy in pa-
tients with advanced ovarian cancer showed no survival benefit in the overall 
study population. However, high-risk patients with a poor prognosis achieved 
a benefit in OS, although it has to be considered that the increase is based on 
data of the ICON7 trial using an unlicensed dose of bevacizumab. Further-
more, the improvements in PFS are not statistically significant. Hence, high 
additional costs and increased AEs stand in contrast to modest improvements 
in efficacy. However, the impact of any prolongation of the patient’s life might 
be relevant even if the addition of bevacizumab is not associated with an im-
proved quality of life. Since the ICON7 trial was conducted with an unli-
censed dose of bevacizumab, it is difficult to assess the applicability of the 
results and, not least, their impact on the treatment costs. 
Facing the recent results from the ICON7 trial and considering the high costs 
for modest improvements – importantly with no increase in the patient’s qual-
ity of life – it is questionable if the broad administration of bevacizumab to 
an unselected patient population (including high-risk and non-high-patients) 
is still appropriate.  
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12 Appendix 
Table 5: Characteristics of the ICON7 trial 
Title: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): 
overall survival results of a phase III randomised trial [18, 19, 23, 37] 
Study identifier ISRCTN91273375, NCT00483782, EudraCT number 2005-003929-2, ICON-7 
Design Phase III, randomised, international, multicentre, open-label trial 
Duration of main phase: Enrolment: 2006-12-18 to 2009-02-16 
End of follow-up: 2013-03-31 
Median follow-up: 48.9 months 
Hypothesis Superiority 
This study was designed and powered to detect differences in PFS and OS between the treatment 
groups. The analysis of OS needed 715 deaths to detect a 10-month improvement in median survival 
from 43 to 53 months (HR 0.81), with 80% power and a two-sided 5% significance level. 
The PFS analysis needed 684 disease progression events to show a 5-month PFS increase from 18 to 
23 months, with 90% power and a two-sided 5% significance level. 
Funding The National Institute for Health Research through the UK National Cancer Research Network, the 
Medical Research Council, and Roche 
Treatments 
groups 
Bevacizumab  
(n = 764) 
6 3-weekly cycles of IV carboplatin (AUC 5 or 6) and paclitaxel 
(175 mg/m2 of body surface area) plus IV bevacizumab (7.5 mg/kg of 
body weight) given concurrently and continued for 12 further 3-weekly 
cycles (with a duration of bevacizumab exposure of about 1 year),  
or until disease progression 
Standard chemotherapy  
(n = 764) 
6 3-weekly cycles of IV carboplatin (AUC 5 or 6) and paclitaxel  
(175 mg/m2 of body surface area) 
Endpoints and 
definitions 
Progression-free 
survival  
(primary endpoint) 
PFS Calculated from the date of randomisation to the date of the first 
indication of disease progression or death, whichever occurred first. 
There was no independent central radiologists’ panel review on 
progression 
Overall survival 
(secondary endpoint) 
OS Calculated from the date of randomisation to the date of death 
from any cause 
Response to therapy - - 
Disease progression  Disease progression was assessed by investigators according to 
RECIST 2000 guidelines, and needed radiological, clinical or 
symptomatic evidence of progression 
Quality of life  QoL Quality of life was assessed with the European Organisation for 
Research and Treatment of Cancer QLQ-C30 and QLQ-OV28 
questionnaires 
Safety - NR 
Database lock NR 
Results and analysis  
Analysis 
description 
Primary analysis 
Intent to treat (included all patients randomly assigned to treatment) 
The primary analysis used an unstratified log-rank test to compare OS between randomised groups. 
Treatment effects were estimated from Cox regression analyses when proportional hazards could be 
assumed. With evidence of non-proportionality, flexible parametric survival models were used to 
smooth survival curves and estimate survival differences during a 5-year period, which is the 
approximate follow-up if patients were enrolled midway through the recruitment period and 
remained in follow-up at the end of the study.  
Analysis 
population  
Inclusion  Age ≥ 18 years 
 Newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer 
 ECOG performance status 0–2 
 FIGO 1988 stage IIb–IV or high risk (grade 3 or clear cell histology) stage I–IIa disease 
 Patients who had undergone debulking cytoreductive surgery or, in advanced 
disease, had a biopsy with no further surgery planned 
 Adequate coagulation parameters and liver, renal and bone marrow function  
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Title: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): 
overall survival results of a phase III randomised trial [18, 19, 23, 37] 
Study identifier ISRCTN91273375, NCT00483782, EudraCT number 2005-003929-2, ICON-7 
Analysis 
population  
(continuation) 
Exclusion  Having other tumour types 
 Previous systemic therapy 
 Planned surgery 
 Uncontrolled hypertension 
Baseline  
characteristics 
 All High risk 
 Bevacizumab 
(n = 764) 
Standard 
therapy 
(n = 764) 
Bevacizumab 
(n = 248) 
Standard 
therapy 
(n = 254) 
Age, median (range) Years 57  
(24–80) 
57  
(18–81) 
60  
(26–80) 
60  
(18–81) 
Race, n (%) 
White 
Asian/Black/Other 
 
730 (96) 
34 (4) 
 
737 (96) 
27 (4) 
 
237 (96) 
11 (4) 
 
242 (95) 
12 (5) 
ECOG PS, n (%) 
0 
1 
2 
Unknown 
 
335 (45) 
366 (49) 
45 (6) 
18 
 
360 (48) 
354 (47) 
41 (5) 
9 
 
100 (41) 
123 (50) 
21 (9) 
4 
 
98 (39) 
135 (53) 
20 (8) 
1 
Origin of cancer, n (%) 
Ovary (epithelial) 
Fallopian tube 
Primary peritoneal 
Multiple sites 
 
673 (88) 
27 (4) 
50 (7) 
14 (2) 
 
667 (87) 
29 (4) 
56 (7) 
12 (2) 
 
207 (83) 
6 (2) 
28 (11) 
7 (3) 
 
210 (83) 
5 (2) 
32 (13) 
7 (3) 
Histology, n (%) 
Serous 
Mucinous 
Endometroid 
Clear cell 
Mixed 
Other 
 
525 (69) 
19 (2) 
60 (8) 
67 (9) 
40 (5) 
53 (7) 
 
529 (69) 
15 (2) 
57 (7) 
60 (8) 
48 (6) 
55 (7) 
 
186 (75) 
6 (2) 
17 (7) 
6 (2) 
14 (6) 
19 (8) 
 
195 (77) 
4 (2) 
14 (6) 
6 (2) 
14 (6) 
21 (8) 
FIGO stage, n (%) 
I/IIA 
IIB/IIC 
III 
IIIA 
IIIB 
IIIC 
IV 
 
67 (9) 
70 (9) 
18 (2) 
22 (3) 
45 (6) 
438 (57) 
104 (14) 
 
75 (10) 
70 (9) 
14 (2) 
32 (4) 
44 (6) 
432 (57) 
97 (13) 
 
 
 
6 (2) 
2 (0.8) 
6 (2) 
130 (52) 
104 (42) 
 
 
 
6 (2) 
2 (0.8) 
8 (3) 
141 (56) 
97 (38) 
Grade, n (%) 
Grade 1 
Grade 2 
Grade 3 
Unknown 
 
41 (5) 
175 (23) 
538 (71) 
10 
 
56 (7) 
142 (19) 
556 (74) 
10 
 
5 (2) 
70 (29) 
169 (69) 
4 
 
10 (4) 
45 (18) 
195 (78) 
4 
Debulking surgery 
Inoperable 
> 1 cm residual 
0–1 cm residual 
0 cm residual 
 
13 (2) 
196 (26) 
194 (25) 
361 (47) 
 
17 (2) 
199 (26) 
175 (23) 
373 (49) 
 
13 (5) 
194 (78) 
20 (8) 
21 (8) 
 
17 (7) 
194 (76) 
19 (7) 
24 (9) 
Abbreviations: AUC = area under the curve, CA-125 = cancer antigen 125, ECOG = Eastern Cooperative Oncology Group, 
FIGO = International Federation of Gynecology and Obstetrics, HR = hazard ratio, IV = intravenous, n = number, NA = 
not applicable, NR = not reported, OS = overall survival, PFS = progression-free survival, RECIST = Response Evaluation 
Criteria In Solid Tumors, QLQ-C30 = quality of life questionnaire – core 30, QLQ-OV28 = quality of life questionnaire – 
ovarian cancer module, QoL = quality of life 
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Table 6: Characteristics of the GOG-218 trial 
Title: Incorporation of bevacizumab in the primary treatment of ovarian cancer [20, 38] 
Study identifier NCT00262847, GOG-0218 trial 
Design International, multicentre, double-blind, placebo-controlled phase III trial  
Duration of main phase: 2005-10 to 2009-6 (enrolment) 
Complete data sweep: 2010-01-02 
Hypothesis Superiority 
A sample size of 1,800 was estimated to provide 90% statistical power to detect a 23% reduction in 
the hazard for progression with either of the 2 bevacizumab-containing regimens versus the control 
regimen while limiting the overall one-sided type I error for both comparisons to 2.5%. The final 
analysis was planned to be conducted after at least 375 patients in the control group died or had 
disease progression.  
Funding National Cancer Institute and Genentech 
Treatments 
groups 
Bevacizumab initiation 
(n = 625) 
Paclitaxel IV 175 mg/m2 of body surface area and carboplatin IV (AUC 6) 
for cycles 1 through 6 + bevacizumab IV (15 mg/kg of body weight) 
added in cycles 2 through 6 + placebo added in cycles 7 through 22 
Bevacizumab throughout 
(n = 623) 
Paclitaxel IV 175 mg/m2 of body surface area and carboplatin IV (AUC 6) 
for cycles 1 through 6 + bevacizumab IV (15mg/kg) added in cycles 2 
through 22 
Control 
(n = 625) 
Paclitaxel IV 175 mg/m2 of body surface area and carboplatin IV (AUC 6) 
for cycles 1 through 6 + placebo added in cycles 2 through 22 
Endpoints and 
definitions 
Overall 
survival 
OS Defined as the observed length of life from entry into the study to 
death, regardless of cause or the date of last contact. 
Primary endpoint was initially specified as OS but was changed to PFS 
during the trial. 
Progression-free 
survival 
PFS Defined as the period from study entry until disease progression 
(according to RECIST criteria 2000), an increase in the CA-125 level 
according to Gynecologic Cancer InterGroup criteria, global deterioration 
of health, death or date of last contact 
Quality of life QoL FACT-O TOI Score 
Safety - AEs were reported until 30 days after the last study treatment had been 
administered and were summarised for patients who received at least 
one cycle of bevacizumab or placebo 
Database lock 2010-02-05 
Results and analysis  
Analysis 
description 
Primary analysis 
Intent-to-treat analysis 
Analysis 
population  
Inclusion  Patients with previously untreated, incompletely resectable stage III or any 
stage IV epithelial ovarian, primary peritoneal, or fallopian tube cancer histo-
logically confirmed by the GOG Pathology Committee after standard abdominal 
surgery with maximal debulking effort within 12 weeks of study entry 
 A GOG performance status score of 0 (fully active) to 2 (ambulatory and 
capable of self-care but unable to work; up and about more than 50% of 
waking hours) 
 No history of clinically significant vascular events or evidence of intestinal 
obstruction 
 Adequate bone marrow function, platelet count, renal function, hepatic 
function and blood coagulation parameters 
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Title: Incorporation of bevacizumab in the primary treatment of ovarian cancer [20, 38] 
Study identifier NCT00262847, GOG-0218 trial 
Analysis 
population  
(continuation) 
Exclusion  Patients with a current diagnosis of borderline epithelial ovarian tumour or 
recurrent invasive epithelial ovarian, primary peritoneal, or fallopian tube 
cancer treated with surgery only 
 Prior radiotherapy to any portion of the abdominal cavity or pelvis 
 Prior chemotherapy for any abdominal or pelvic tumour, including neoadjuvant 
chemotherapy for ovarian, primary peritoneal or fallopian tube cancer 
 Patients who had received any targeted therapy or hormonal therapy for 
management of their epithelial ovarian or primary peritoneal cancer 
 Patients with serious non-healing wound, ulcer, or bone fracture 
 Patients with active bleeding or pathologic conditions that carry a high risk  
of bleeding 
 Clinically significant cardiovascular disease 
Characteristics  Bevacizumab 
initiation 
(n = 625) 
Bevacizumab 
throughout  
(n = 623) 
 
Control  
(n = 625) 
Median age (range), years 60 (24–88) 60 (22–89) 60 (25–86) 
Race or ethnic group, n (%) 
Non-Hispanic white 
Asian 
Non-Hispanic black 
Hispanic 
Other or unspecified 
 
519 (83.0) 
37 (5.9) 
28 (4.5) 
28 (4.5) 
13 (2.1) 
 
521 (83.6) 
39 (6.3) 
27 (4.3) 
25 (4.0) 
11 (1.8) 
 
526 (84.2) 
41 (6.6) 
25 (4.0) 
21 (3.4) 
12 (1.9) 
GOG performance status, n (%) 
0 
1 
2 
 
315 (50.4) 
270 (43.2) 
40 (6.4) 
 
305 (49.0) 
267 (42.9) 
51 (8.2) 
 
311 (49.8) 
272 (43.5) 
42 (6.7) 
Stage/debulking status, n (%) 
III (macroscopic, ≤ 1 cm) 
III (> 1 cm) 
IV 
 
205 (32.8) 
256 (41.0) 
164 (26.2) 
 
216 (34.7) 
242 (38.8) 
165 (26.5) 
 
218 (34.9) 
254 (40.6) 
153 (24.5) 
Histologic type, n (%) 
Serous 
adenocarcinoma 
Endometrioid 
Clear cell 
Mucinous 
Other or not  
specified  
 
 
519 (83.0) 
14 (2.2) 
23 (3.7) 
5 (0.8) 
 
64 (10.2) 
 
 
524 (84.1) 
24 (3.9) 
20 (3.2) 
8 (1.3) 
47 (7.5) 
 
 
541(86.6) 
21 (3.4) 
12 (1.9) 
6 (1.0) 
45 (7.2) 
Tumour grade, n (%) 
3 
2 
1 
Not graded 
 
465 (74.4) 
86 (13.8) 
28 (4.5) 
46 (7.4) 
 
460 (73.8) 
97 (15.6) 
18 (2.9) 
48 (7.7) 
 
445 (71.2) 
102 (16.3) 
36 (5.8) 
42(6.7) 
Abbreviations: AUC = area under the curve, FACT-O TOI = Trial Outcome Index of the Functional Assessment of Cancer 
Therapy – Ovary, GOG = Gynecologic Oncology Group, HR = hazard ratio, IV = intravenous, n = number, NA = not 
applicable, NR = not reported, OS = overall survival, PFS = progression-free survival, QoL = quality of life 
 
